The toxic effects of an acute overdosage of Wigraine® are due primarily to the ergotamine component. The amount of caffeine is such that its toxic effects will be overshadowed by those of ergotamine. Symptoms include vomiting, numbness, tingling, pain and cyanosis of the extremities associated with diminished or absent peripheral pulses, hypertension or hypotension, drowsiness, stupor, coma, convulsions and shock. Treatment consists of removal of the offending drug by induction of emesis, gastric lavage and catharsis. Maintenance of adequate pulmonary ventilation, correction of hypotension, and control of convulsions are important considerations. Treatment of peripheral vasospasm should consist of warmth, but not heat, and protection of the ischemic limbs. Vasodilators may be used with benefit but caution must be exercised to avoid aggravating an already existing hypotension. The LD50 limits of the various components as outlined in NIOSH 1978 Registry of Toxic Effects of Chemical Substances, published by U.S. Department of Health, Education and Welfare are as follows: Ergotamine Tartrate IV LD50 in rats = 80mg/Kg, Caffeine IV LD50 in rats = 105mg/Kg.

Wigraine® can cause fetal harm when administered to a pregnant women. It can produce prolonged uterine contractions which can result in abortion. Wigraine® is contraindicated in women who are or may become pregnant. If this is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazard to the fetus.

Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function, sepsis and hypersensitivity to any of the components.

Bookmark this page: